Related Experiment Video

Updated: Aug 1, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.2K

Effect of β1-adrenergic receptor gene polymorphism on ventricular arrhythmia and prognosis after myocardial

Tao Ran1,2, Zong Xiaojuan2, Pang Yang1

  • 1Department of Cardiology, Zhongshan Hospital.

Coronary Artery Disease
|April 27, 2023
PubMed

Insights

The Arg389Arg genotype in acute myocardial infarction (AMI) patients is linked to increased heart damage and a higher risk of ventricular arrhythmias. This finding highlights the role of genetic variations in AMI complications.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Ventricular arrhythmia is a frequent complication following acute myocardial infarction (AMI).
  • The Arg389Gly polymorphism in the β1-adrenergic receptor gene may influence outcomes in AMI patients.

Purpose of the Study:

  • To investigate the association between the β1-adrenergic receptor Arg389Gly polymorphism and clinical outcomes in patients with acute myocardial infarction.
  • To determine if specific genotypes correlate with myocardial damage, cardiac function, and the incidence of ventricular arrhythmias.

Main Methods:

  • Retrospective analysis of 213 acute myocardial infarction patients.
  • Genotyping for the Arg389Gly polymorphism of the β1-adrenergic receptor.
  • Clinical data collection including cardiac troponin T (cTnT), pro-BNP levels, ejection fraction, and ECG monitoring for ventricular arrhythmias and premature ventricular contractions (PVCs).
  • Statistical analysis using SPSS, with significance set at P < 0.05.

Main Results:

  • The Arg389Arg genotype was observed in 65.7% of patients, Arg389Gly in 21.6%, and Gly389Gly in 12.7%.
  • Patients with Arg389Arg genotype showed significantly higher cTnT and pro-BNP levels, and lower ejection fraction compared to other genotypes.
  • The Arg389Arg genotype was associated with a higher incidence of ventricular tachycardia and PVCs compared to the Gly389Gly genotype.

Conclusions:

  • The Arg389Arg genotype is associated with greater myocardial damage and impaired cardiac function in AMI patients.
  • This genotype is linked to an increased probability of developing ventricular arrhythmia following acute myocardial infarction.
Abstract

More Related Videos

Cardiac Response to &#946;-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.7K
Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

13.5K

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
406
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
530
Antiarrhythmic Drugs: Class II Agents as &#946;-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
787
Adrenergic Antagonists: Pharmacological Actions of &#946;-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
902
Adrenergic Receptors: &#946; Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.8K
Adrenergic Antagonists: Chemistry and Classification of &#946;-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
686